NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis
Open Access
- 10 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (4) , 579-591
Abstract
N-Myc downstream regulated gene 1 (NDRG1) suppresses metastasis in many human malignancies, including breast cancer, yet has been associated with worse survival in patients with inflammatory breast cancer. The role of NDRG1 in the pathobiology of aggressive breast cancers remains elusive. To study the role of NDRG1 in tumor growth and brain metastasis in vivo, we transplanted cells into cleared mammary fat pads or injected them in tail veins of SCID/Beige mice (n = 7-10 per group). NDRG1 protein expression in patient breast tumors (n = 216) was assessed by immunohistochemical staining. Kaplan-Meier method with 2-sided log-rank test was used to analyze the associations between NDRG1 and time-to-event outcomes. A multivariable Cox regression model was used to determine independent prognostic factors. All statistical tests were 2-sided. We generated new sublines that exhibited a distinct propensity to metastasize to the brain. NDRG1-high–expressing cells produced more prevalent brain metastases (100% vs 44.4% for NDRG1-low sublines, P = .01, Fisher’s exact test), greater tumor burden, and reduced survival in mice. In aggressive breast cancer cell lines, silencing NDRG1 led to reduced migration, invasion, and tumor-initiating cell subpopulations. In xenograft models, depleting NDRG1 inhibited primary tumor growth and brain metastasis. In patient breast tumors, NDRG1 was associated with aggressiveness: NDRG1-high expression was also associated with shorter overall survival (hazard ratio [HR] = 2.27, 95% confidence interval [95% CI] = 1.20 to 4.29, P = .009) and breast cancer–specific survival (HR = 2.19, 95% CI = 1.07 to 4.48, P = .03). Multivariable analysis showed NDRG1 to be an independent predictor of overall survival (HR = 2.17, 95% CI = 1.10 to 4.30, P = .03) and breast cancer–specific survival rates (HR = 2.27, 95% CI = 1.05 to 4.92, P = .04). We demonstrated that NDRG1 drives tumor progression and brain metastasis in aggressive breast cancers and that NDRG1-high expression correlates with worse clinical outcomes, suggesting that NDRG1 may serve as a therapeutic target and prognostic biomarker in aggressive breast cancers.Keywords
Funding Information
- American Cancer Society Research Scholar Grant (RSG-19–126–01)
- Komen Career Catalyst Research Grant (CCR16377813)
- Startup and Institutional Research Grants from MD Anderson
- The Morgan Welch Inflammatory Breast Cancer Boot Walk Fund
- NCI/NIH Cancer Center Support (P30 CA016672)
- NCI’s Research Specialist (1 R50 CA243707-01A1)
- The University of Texas MD Anderson Cancer Center
This publication has 44 references indexed in Scilit:
- Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancerJournal of Biomedical Science, 2013
- N‐myc downstream regulated gene 1 modulates Wnt‐β‐catenin signalling and pleiotropically suppresses metastasisEMBO Molecular Medicine, 2012
- NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinomaCancer Letters, 2011
- Down-Regulation of NDRG1 Promotes Migration of Cancer Cells during ReoxygenationPLOS ONE, 2011
- N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivoSurgery, 2011
- Incidence of and survival following brain metastases among women with inflammatory breast cancerAnnals of Oncology, 2010
- Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinomaCancer Letters, 2008
- N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cellsCancer Letters, 2008
- Squamous Cell Carcinoma of the BreastJournal of Clinical Oncology, 2005
- Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progressionOncogene, 2004